Study on Torvutatug Samrotecan With or Without Bevacizumab for Maintenance Treatment of Platinum-sensitive Relapsed Ovarian Cancer

Inclusion Criteria

• Women with confirmed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer.
• Must provide a previous tumor sample for analysis.
• Have received at least one, but no more than two, previous cancer treatments.
• Cancer must have returned at least 6 months after the last platinum chemotherapy treatment.
• Have completed 4-6 cycles of platinum-based chemotherapy in their current treatment phase.
• If assigned to receive bevacizumab, must have had at least 3 cycles of bevacizumab with 3 cycles of platinum-based chemotherapy before starting the study.
• Cancer must not be progressing after completing the current chemotherapy.
• If they have a BRCA 1/2 mutation, must have previously received a PARP inhibitor unless unable to due to medical reasons.

Exclusion Criteria

• Have tumors that are not epithelial in origin, or have borderline, clear cell, mucinous, carcinosarcoma, or low-grade epithelial tumors.
• Have a history of lung conditions like ILD/pneumonitis that needed steroids or oxygen, or currently have these conditions.
• Have a non-healing wound, active ulcer, or bone fracture (if receiving bevacizumab).
• Have an active or ongoing bowel obstruction (if receiving bevacizumab).
• Have previously been treated with any FRα-targeted therapy or certain antibody-drug conjugates.